Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ZEISS to Acquire Xradia to Complement its Microscopy Business

Published: Friday, June 14, 2013
Last Updated: Friday, June 14, 2013
Bookmark and Share
Expanding from light and electron microscopy into X-ray microscopy solutions.

ZEISS has announced the planned acquisition of the US-based Xradia, Inc. Xradia is an medium-size company providing innovative 3D X-ray microscopes for industrial and academic research applications.

The closing of the transaction is subject to the fulfillment of customary closing conditions including a required filing with the U.S. competition authorities.

After closing, Xradia, Inc. will operate under the new name Carl Zeiss X-ray Microscopy, Inc.

X-ray microscopes help to advance innovation in science and industry and can be used for many applications.

During the last years Xradia recorded strong growth in revenue, profits, and number of employees based on its excellent technology position meeting customer needs worldwide.

Xradia has become a provider of established solutions for advanced material research, natural resources and geology, semiconductor process optimization as well as the life sciences. Both parties have agreed to keep the purchase price confidential.

“For ZEISS the microscopy business is a strong pillar in its portfolio. The investment in Xradia underlines our strategy to grow with the most innovative and future-oriented technologies”, stated Dr. Michael Kaschke, President and CEO of Carl Zeiss AG.

Dr. Kaschke continued, “The decision to acquire Xradia was made after careful consideration of its product lines as well as sales and service coverage. By combining the product lines, ZEISS will be able to better serve the growing demands in multimodal microscopic imaging and to develop solutions which create new values for our customers in science and industry.”

Dr. Ulrich Simon, head of the ZEISS Microscopy business group further said: "This step is extremely exciting for us as it demonstrates our clear focus to take microscopy to the next level. Based on our unique portfolio of light, electron and ion microscopes, we are now adding the capability of 3D imaging within objects at unprecedented resolution using X-ray microscopy. This will enable new applications and make the workflows in multimodal imaging easier and more efficient to use for our customers worldwide."

“We could not be more pleased than to join such an outstanding and well-regarded global organization as ZEISS. Xradia’s significant growth over the past years demonstrates the value of high resolution 3D X-ray microscopy for researchers worldwide. The additional resources offered by ZEISS will undoubtedly facilitate even more rapid growth of X-ray microscopy solutions as well as provide additional value for our existing customer base.”, adds Rod Browning, President and CEO of Xradia, Inc.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Bioreactors Ready for the Big Time
Bioreactors are passive filtration systems that can reduce nitrate losses from farm fields.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
‘Mini-Brains’ to Study Zika
Novel tool expected to speed research on brain and drug development.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!